title: Glucose-lowering therapy in type 2 diabetes. New hope after the EMPA-REG outcome trial.
abstract: Prevention of cardiovascular morbidity and mortality remains the key factor in the treatment of type 2 diabetes (T2DM). In the early phase of T2DM, multifactorial intervention is mandatory and glucose levels should be near normal, in particular in younger patients presenting with the highest cardiovascular risk. Anti-diabetic drugs without any risk for hypoglycaemia should be preferred in order to reduce clinical inertia and increase the long-term adherence to the treatment. In patients already presenting with cardiovascular disease, the best outcome may be expected with the triple oral therapy of metformin, pioglitazone, and empagliflozin, although a controlled prospective study versus insulin therapy is needed to confirm the expectation.
authors.affiliation: Medical University Vienna, Wien, Österreich. guntram.schernthaner@meduniwien.ac.at.
authors.forename: G
authors.initials: G
authors.lastname: Schernthaner
authors.affiliation: Department of Medicine II, Division of Angiology, Medical University Vienna, Wien, Österreich.
authors.forename: G-H
authors.initials: GH
authors.lastname: Schernthaner
mesh_terms: D002318:Cardiovascular Diseases / Q000209:etiology* / Q000517:prevention & control*; D003924:Diabetes Mellitus, Type 2 / Q000150:complications* / Q000188:drug therapy*; D019317:Evidence-Based Medicine; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage*; D016896:Treatment Outcome
chemical_list: D007004:Hypoglycemic Agents
keywords: Cardiovascular disease; EMPA-REG outcome; Glucose-lowering therapy; PROactive; Type 2 diabetes